These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
611 related articles for article (PubMed ID: 3756906)
1. Mechanism of antitumor activity in mice for anti-epidermal growth factor receptor monoclonal antibodies with different isotypes. Masui H; Moroyama T; Mendelsohn J Cancer Res; 1986 Nov; 46(11):5592-8. PubMed ID: 3756906 [TBL] [Abstract][Full Text] [Related]
2. Cytotoxicity against human tumor cells mediated by the conjugate of anti-epidermal growth factor receptor monoclonal antibody to recombinant ricin A chain. Masui H; Kamrath H; Apell G; Houston LL; Mendelsohn J Cancer Res; 1989 Jul; 49(13):3482-8. PubMed ID: 2786451 [TBL] [Abstract][Full Text] [Related]
3. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. Fan Z; Masui H; Altas I; Mendelsohn J Cancer Res; 1993 Sep; 53(18):4322-8. PubMed ID: 8364927 [TBL] [Abstract][Full Text] [Related]
4. Impact of human IgA antibodies on complement-dependent cytotoxicity mediated by combinations of EGF-R-directed antibodies. Lohse S; Peipp M; Beyer T; Valerius T; Dechant M Arch Immunol Ther Exp (Warsz); 2010 Aug; 58(4):303-12. PubMed ID: 20508996 [TBL] [Abstract][Full Text] [Related]
5. Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo. Drebin JA; Link VC; Greene MI Oncogene; 1988 Apr; 2(4):387-94. PubMed ID: 2896329 [TBL] [Abstract][Full Text] [Related]
6. Two distinct mechanisms of antitumor activity mediated by the combination of interleukin 2 and monoclonal antibodies. Vuist WM; van Buitenen F; Hekman A; Melief CJ Cancer Res; 1990 Sep; 50(18):5767-72. PubMed ID: 1697500 [TBL] [Abstract][Full Text] [Related]
7. Enhanced antitumor effects of CD20 over CD19 monoclonal antibodies in a nude mouse xenograft model. Hooijberg E; van den Berk PC; Sein JJ; Wijdenes J; Hart AA; de Boer RW; Melief CJ; Hekman A Cancer Res; 1995 Feb; 55(4):840-6. PubMed ID: 7531616 [TBL] [Abstract][Full Text] [Related]
8. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Masui H; Kawamoto T; Sato JD; Wolf B; Sato G; Mendelsohn J Cancer Res; 1984 Mar; 44(3):1002-7. PubMed ID: 6318979 [TBL] [Abstract][Full Text] [Related]
9. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Fan Z; Baselga J; Masui H; Mendelsohn J Cancer Res; 1993 Oct; 53(19):4637-42. PubMed ID: 8402640 [TBL] [Abstract][Full Text] [Related]
10. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity. Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715 [TBL] [Abstract][Full Text] [Related]
11. Combinations of anti-transferrin receptor monoclonal antibodies inhibit human tumor cell growth in vitro and in vivo: evidence for synergistic antiproliferative effects. White S; Taetle R; Seligman PA; Rutherford M; Trowbridge IS Cancer Res; 1990 Oct; 50(19):6295-301. PubMed ID: 2400993 [TBL] [Abstract][Full Text] [Related]
12. Induction of apoptosis by monoclonal antibody anti-APO-1 class switch variants is dependent on cross-linking of APO-1 cell surface antigens. Dhein J; Daniel PT; Trauth BC; Oehm A; Möller P; Krammer PH J Immunol; 1992 Nov; 149(10):3166-73. PubMed ID: 1431095 [TBL] [Abstract][Full Text] [Related]
13. Potentiation by interleukin 2 of Burkitt's lymphoma therapy with anti-pan B (anti-CD19) monoclonal antibodies in a mouse xenotransplantation model. Vuist WM; v Buitenen F; de Rie MA; Hekman A; Rümke P; Melief CJ Cancer Res; 1989 Jul; 49(14):3783-8. PubMed ID: 2472198 [TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor receptor as a target for therapy with antireceptor monoclonal antibodies. Mendelsohn J J Natl Cancer Inst Monogr; 1992; (13):125-31. PubMed ID: 1389685 [TBL] [Abstract][Full Text] [Related]
15. Influence of antibody isotype on passive serotherapy of lymphoma. Denkers EY; Badger CC; Ledbetter JA; Bernstein ID J Immunol; 1985 Sep; 135(3):2183-6. PubMed ID: 2862210 [TBL] [Abstract][Full Text] [Related]
16. Tumor cell lysis and tumor growth inhibition by the isotype variants of MAb BR55-2 directed against Y oligosaccharide. Steplewski Z; Lubeck MD; Scholz D; Loibner H; McDonald Smith J; Koprowski H In Vivo; 1991; 5(2):79-83. PubMed ID: 1768791 [TBL] [Abstract][Full Text] [Related]
17. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Yang XD; Jia XC; Corvalan JR; Wang P; Davis CG; Jakobovits A Cancer Res; 1999 Mar; 59(6):1236-43. PubMed ID: 10096554 [TBL] [Abstract][Full Text] [Related]
18. Differentiation or immune destruction: two pathways for therapy of squamous cell carcinomas with antibodies to the epidermal growth factor receptor. Modjtahedi H; Eccles S; Sandle J; Box G; Titley J; Dean C Cancer Res; 1994 Apr; 54(7):1695-701. PubMed ID: 8137284 [TBL] [Abstract][Full Text] [Related]
19. Synergistic antitumor effects of BCG and monoclonal antibodies capable of inducing antibody-dependent cell-mediated cytotoxicity. Komuta K; Kawase I; Ogura T; Masuno T; Yokota S; Hosoe S; Ikeda T; Shirasaka T; Kishimoto S Jpn J Cancer Res; 1987 Feb; 78(2):185-92. PubMed ID: 3104261 [TBL] [Abstract][Full Text] [Related]
20. Therapy with unlabeled and 131I-labeled pan-B-cell monoclonal antibodies in nude mice bearing Raji Burkitt's lymphoma xenografts. Buchsbaum DJ; Wahl RL; Normolle DP; Kaminski MS Cancer Res; 1992 Dec; 52(23):6476-81. PubMed ID: 1423295 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]